Abbott Laboratories
ABT
130.98
USD+1.28
(+0.99%)Day's range
129.66
132.71
52 wk Range
99.71
141.23
Key ratios
Statements Highlights
| Period Ending | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
|---|---|---|---|---|---|---|
| Total Revenue | 34,608,000,000 | 43,075,000,000 | 43,653,000,000 | 40,109,000,000 | 41,950,000,000 | |
| Gross Profit | 19,605,000,000 | 24,538,000,000 | 24,511,000,000 | 22,134,000,000 | 23,244,000,000 | |
| Operating Income | 5,357,000,000 | 8,425,000,000 | 8,362,000,000 | 6,478,000,000 | 6,825,000,000 | |
| Net Income | 4,495,000,000 | 7,071,000,000 | 6,933,000,000 | 5,723,000,000 | 13,402,000,000 | |
| Total Assets | 72,548,000,000 | 75,196,000,000 | 74,438,000,000 | 73,214,000,000 | 81,414,000,000 | |
| Total Current Liabilities | 11,907,000,000 | 13,105,000,000 | 15,489,000,000 | 13,841,000,000 | 14,157,000,000 | |
| Total Equity | 33,003,000,000 | 36,024,000,000 | 36,905,000,000 | 38,827,000,000 | 47,901,000,000 | |
| Free Cash Flow | 5,724,000,000 | 8,648,000,000 | 7,804,000,000 | 5,059,000,000 | 6,351,000,000 | |
| Cash from Operations | 7,901,000,000 | 10,533,000,000 | 9,581,000,000 | 7,261,000,000 | 8,558,000,000 | |
| Cash from Investing | -2,215,000,000 | -2,008,000,000 | -1,740,000,000 | -3,133,000,000 | -2,338,000,000 | |
| Cash from Financing | -2,779,000,000 | -5,494,000,000 | -7,636,000,000 | -7,091,000,000 | -5,404,000,000 | |
| Net Change in Cash | 2,978,000,000 | 2,961,000,000 | 83,000,000 | -2,986,000,000 | 720,000,000 |
Dividends
Analyst Recomendations
Overall consensus
Buy